High Mobility Group Box 1 and Traumatic Brain Injury

Home > Journals > Biomedical & Life Sciences | Medicine & Healthcare >JBBS

ISSN Print: 2160-5866
ISSN Online: 2160-5874

Website: https://www.scirp.org/journal/jbbs
E-mail: jbbs@scirp.org

Citations h5-index & Ranking

Submission

"High Mobility Group Box 1 and Traumatic Brain Injury"
written by Seidu A. Richard, Wu Min, Zhaoliang Su, Huaxi Xu,
published by Journal of Behavioral and Brain Science, Vol.7 No.2, 2017

has been cited by the following article(s):

Google Scholar
CrossRef

[1]	Potential neuroprotective effect of the HMGB1 inhibitor Glycyrrhizin in neurological disorders
	2020

[2]	Elucidating the novel biomarker and therapeutic potentials of High-mobility group box 1 in Subarachnoid hemorrhage: A review
	2019

[3]	The Therapeutic Potential of Resveratrol in Gliomas
	2019

[4]	HMGB1: A Common Biomarker and Potential Target for TBI, Neuroinflammation, Epilepsy, and Cognitive Dysfunction
	Frontiers in neuroscience, 2018

[5]	Pivotal Pathogenic and Biomarker Role of Chlamydia Pneumoniae in Neurovascular Diseases
	Current Neurovascular Research, 2018

[6]	Myeloid-derived Suppressor Cells in Cancer: A Review on the Pathogenesis and Therapeutic Potentials
	2018

[7]	High-mobility group box 1 is a promising diagnostic and therapeutic monitoring biomarker in Cancers: A review
	2018

[8]	Pivotal neuroinflammatory and therapeutic role of high mobility group box 1 in ischemic stroke
	2017

[9]	Epochal neuroinflammatory role of high mobility group box 1 in central nervous system diseases
	2017

[10]	Carcinogenic and therapeutic role of high-mobility group box 1 in cancer: is it a cancer facilitator, a cancer inhibitor or both
	2017

[11]	Post-translational modifications of high mobility group box 1 and cancer
	American journal of translational research, 2017

[12]	The pivotal neuroinflammatory, therapeutic and neuroprotective role of alpha-mangostin
	2017

[1]	Potential Neuroprotective Effect of the HMGB1 Inhibitor Glycyrrhizin in Neurological Disorders ACS Chemical Neuroscience, 2020 DOI:10.1021/acschemneuro.9b00640

[2]	Elucidating the novel biomarker and therapeutic potentials of High-mobility group box 1 in Subarachnoid hemorrhage: A review AIMS Neuroscience, 2019 DOI:10.3934/Neuroscience.2019.4.316

[3]	HMGB1: A Common Biomarker and Potential Target for TBI, Neuroinflammation, Epilepsy, and Cognitive Dysfunction Frontiers in Neuroscience, 2018 DOI:10.3389/fnins.2018.00628

[4]	High-mobility group box 1 is a promising diagnostic and therapeutic monitoring biomarker in Cancers: A review AIMS Molecular Science, 2018 DOI:10.3934/molsci.2018.4.183

[5]	Myeloid-derived Suppressor Cells in Cancer: A Review on the Pathogenesis and Therapeutic Potentials The Open Cancer Immunology Journal, 2018 DOI:10.2174/1876401001807010016

[6]	Epochal neuroinflammatory role of high mobility group box 1 in central nervous system diseases AIMS Molecular Science, 2017 DOI:10.3934/molsci.2017.2.185

[7]	Pivotal neuroinflammatory and therapeutic role of high mobility group box 1 in ischemic stroke Bioscience Reports, 2017 DOI:10.1042/BSR20171104